Gilead Sciences, Inc. (GILD) Shares Sold by Achmea Investment Management B.V.

Achmea Investment Management B.V. reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 34.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,671 shares of the biopharmaceutical company’s stock after selling 64,990 shares during the period. Achmea Investment Management B.V.’s holdings in Gilead Sciences were worth $8,608,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Penserra Capital Management LLC grew its stake in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Gilead Sciences during the second quarter worth $147,000. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Gilead Sciences by 29.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 480 shares during the last quarter. Rowland & Co. Investment Counsel ADV bought a new stake in shares of Gilead Sciences during the second quarter worth $153,000. Finally, Capstone Investment Advisors Netherlands B.V. bought a new stake in shares of Gilead Sciences during the second quarter worth $172,000. Institutional investors and hedge funds own 76.23% of the company’s stock.

In other news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.56, for a total transaction of $6,054,372.48. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total transaction of $2,066,250.00. The disclosure for this sale can be found here. Insiders have sold 494,999 shares of company stock worth $37,404,139 in the last ninety days. Insiders own 1.30% of the company’s stock.

GILD has been the topic of a number of research reports. Berenberg Bank set a $96.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. Royal Bank of Canada initiated coverage on shares of Gilead Sciences in a research note on Thursday, September 14th. They set an “outperform” rating and a $94.00 target price on the stock. J P Morgan Chase & Co set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and set a $81.00 target price (up previously from $73.00) on shares of Gilead Sciences in a research note on Thursday, August 31st. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus price target of $85.11.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $74.34 on Friday. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The company has a market cap of $97,080.00, a price-to-earnings ratio of 7.94, a price-to-earnings-growth ratio of -1.27 and a beta of 1.13. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.75 earnings per share. equities research analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.80%. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.66%.

COPYRIGHT VIOLATION WARNING: This report was originally published by Week Herald and is the property of of Week Herald. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://weekherald.com/2017/12/15/gilead-sciences-inc-gild-shares-sold-by-achmea-investment-management-b-v.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply